Keensight Capital Acquires Majority Stake in Biovian

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare

May 25, 2021

Healthcare Services

Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.

Keensight Capital Acquires Majority Stake in Isto Biologics

September 22, 2025

Medical Devices

Keensight Capital has acquired a majority stake in Isto Biologics, a US-based regenerative MedTech company focused on orthobiologic bone graft solutions. Thompson Street Capital Partners will retain a minority stake alongside Isto's management; Keensight plans to support Isto's international expansion and pursue additional acquisitions to accelerate growth.

Keensight Capital Acquires Majority Stake in BYG4lab

July 22, 2022

Software

Keensight Capital has acquired a majority stake in BYG4lab, a France-headquartered provider of data management software for medical laboratories. The PE firm will support BYG4lab's international expansion (Europe and North America), product diversification and accelerated growth both organically and via acquisitions.

Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners

December 20, 2022

Software

Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.

BYG4lab to Acquire Finbiosoft with Support from Keensight Capital

March 14, 2024

Software

BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.